Aktis Oncology
AKTS
17.53
-0.47
-2.64%
Aktis Oncology
US · AKTS
#3249 by market cap
Listed 2026
17.53
-0.47
-2.64%
Live - 5344 symbols - heartbeat 246s ago
· 2026-10-08 09:58
Pre-market
17.87
-0.72%
After-hours
18.00
0.00%
- Market cap
- 974.75M
- P/E (TTM)i
- -12.81
- P/Bi
- 2.01
- EPSi
- -1.15
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on AKTS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.5 percentage points.
Institutional ownership
- Held by institutions
- 89.77% -0.50pp
- Institutions
- 144 +3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund30.83%
Hedge Fund23.51%
Mutual Fund23.03%
Public Company11.98%
Individual/Insider0.46%
Family Office/Trust0.20%
Private Company0.11%
Other9.77%
Top holders as of 2026-01-12
Eli Lilly and Company
11.41% · 6.34M sh
EcoR1 Capital, LLC
10.56% · 5.88M sh
Vida Ventures Advisors, LLC
10.48% · 5.83M sh
MPM BioImpact LLC
8.69% · 4.84M sh
CHI Advisors LLC
5.52% · 3.07M sh
T. Rowe Price Group, Inc.
5.06% · 2.81M sh
Blue Owl Credit Private Fund Advisors LLC
4.37% · 2.43M sh
BlackRock
4.10% · 2.28M sh
Wellington Management Group
3.54% · 1.97M sh
RTW Investments, LP
2.86% · 1.59M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
32 filings tracked · 7 buys · 5 sells
| Name | Role | Stake |
|---|---|---|
| Eli Lilly and Company | -- | 11.41% |
| EcoR1 Capital, LLC | -- | 10.56% |
| Vida Ventures Advisors, LLC | -- | 10.48% |
| Paul Feldman | Chief Scientific Officer | 0.26% |
| Matthew Roden | Chief Executive Officer | 0.17% |
| Lloyd Segal | Independent Director | 0.04% |
| MPM BioImpact LLC | -- | -- |
| Todd Foley | Chairperson | -- |
| Helen Kim | Independent Director | -- |
| Michael Sherman | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-22 | Akos Czibere | Chief Medical Officer | Derivative Exercise and Sale | -12,500 | $4.95–21.03 |
| 2026-07-19 | Ken Herrmann | Chair of Scientific Advisory Board & Independent Director | Derivative Exercise and Sale | -4,856 | $0.08–24.56 |
| 2026-07-16 | Ken Herrmann | Chair of Scientific Advisory Board & Independent Director | Derivative Exercise and Sale | -3,065 | $0.08–25.21 |
| 2026-07-07 | Shulamit Ron-Bigger | Chief Operating Officer | Derivative Exercise and Sale | -50,000 | $3.66–28.75 |
| 2026-07-07 | Akos Czibere | Chief Medical Officer | Derivative Exercise and Sale | -50,000 | $4.95–28.71 |
| 2026-01-11 | MPM BioImpact LLC | -- | Private Acquisition | +1,112,777 | $18.00 |
| 2026-01-11 | MPM BioImpact LLC | -- | Derivative Exercise and Retained | +8,208,187 | -- |
| 2026-01-11 | Eli Lilly and Company | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-01-11 | Lloyd Segal | Independent Director | Derivative Exercise and Retained | +19,631 | -- |
| 2026-01-11 | EcoR1 Capital, LLC | -- | Private Acquisition | +2,222,222 | $18.00 |
| 2026-01-11 | EcoR1 Capital, LLC | -- | Derivative Exercise and Retained | +2,602,247 | -- |
| 2026-01-11 | Vida Ventures Advisors, LLC | -- | Private Acquisition | +835,000 | $18.00 |
| 2026-01-11 | Vida Ventures Advisors, LLC | -- | Derivative Exercise and Retained | +4,994,212 | -- |
| 2026-01-07 | MPM BioImpact LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Todd Foley | Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Helen Kim | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Michael Sherman | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Lloyd Segal | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Mary Thistle | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Matthew Roden | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:58:12 · For reference only, not investment advice and not tailored to your situation.